JP7595459B2 - ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物 - Google Patents

ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物 Download PDF

Info

Publication number
JP7595459B2
JP7595459B2 JP2020507498A JP2020507498A JP7595459B2 JP 7595459 B2 JP7595459 B2 JP 7595459B2 JP 2020507498 A JP2020507498 A JP 2020507498A JP 2020507498 A JP2020507498 A JP 2020507498A JP 7595459 B2 JP7595459 B2 JP 7595459B2
Authority
JP
Japan
Prior art keywords
acnes
composition
bacteriophage
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517735A5 (enExample
JP2020517735A (ja
Inventor
バルマー，ユグ
ファン・プローイェン，ナンシー
Original Assignee
ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド filed Critical ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド
Publication of JP2020517735A publication Critical patent/JP2020517735A/ja
Publication of JP2020517735A5 publication Critical patent/JP2020517735A5/ja
Priority to JP2024063779A priority Critical patent/JP7801389B2/ja
Application granted granted Critical
Publication of JP7595459B2 publication Critical patent/JP7595459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01052—Beta-N-acetylhexosaminidase (3.2.1.52)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01001—Pyrroline-2-carboxylate reductase (1.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21064—Peptidase K (3.4.21.64)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020507498A 2017-04-21 2018-04-20 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物 Active JP7595459B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063779A JP7801389B2 (ja) 2017-04-21 2024-04-11 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488326P 2017-04-21 2017-04-21
US62/488,326 2017-04-21
PCT/US2018/028556 WO2018195415A1 (en) 2017-04-21 2018-04-20 Compositions comprising propionibacterium acnes bacteriophages for treating acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063779A Division JP7801389B2 (ja) 2017-04-21 2024-04-11 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物

Publications (3)

Publication Number Publication Date
JP2020517735A JP2020517735A (ja) 2020-06-18
JP2020517735A5 JP2020517735A5 (enExample) 2021-05-27
JP7595459B2 true JP7595459B2 (ja) 2024-12-06

Family

ID=63857016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020507498A Active JP7595459B2 (ja) 2017-04-21 2018-04-20 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP2024063779A Active JP7801389B2 (ja) 2017-04-21 2024-04-11 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063779A Active JP7801389B2 (ja) 2017-04-21 2024-04-11 ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物

Country Status (8)

Country Link
US (3) US20210338569A1 (enExample)
EP (1) EP3612200A4 (enExample)
JP (2) JP7595459B2 (enExample)
KR (2) KR102799152B1 (enExample)
CN (1) CN110799203A (enExample)
AU (1) AU2018255972B2 (enExample)
CA (1) CA3060415A1 (enExample)
WO (1) WO2018195415A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017254684A1 (en) 2016-04-21 2018-12-06 Weiss Bioscience, Inc. Compositions and methods for treatment of skin disorders
JP7595459B2 (ja) 2017-04-21 2024-12-06 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
US20210177920A1 (en) * 2017-12-05 2021-06-17 Biomx Ltd. Bacteriophage treatment for acne and biofilms
WO2020104216A1 (en) * 2018-11-19 2020-05-28 Unilever N.V. An antimicrobial composition for selectively inhibiting growth of p. acnes bacteria
KR20210033627A (ko) * 2019-09-19 2021-03-29 성균관대학교산학협력단 레조르시놀 또는 페닐에틸레조르시놀을 포함하는 공기오염물질에 의해 유발되는 피부 질환 예방, 치료, 또는 개선용 조성물
CN115813869A (zh) * 2022-12-15 2023-03-21 深圳市奥极因科技有限公司 一种感知进食状态智能给药的重组菌含片
WO2025024918A1 (en) * 2023-07-28 2025-02-06 Kane Biotech Inc. Composition, methods, and uses thereof for acne prevention, reduction, and treatment
CO2023015253A1 (es) * 2023-11-10 2024-02-15 Univ Los Andes Fago funcionalizado para tratamiento de acné

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008297241A (ja) 2007-05-31 2008-12-11 Fujifilm Corp ニキビ用皮膚外用剤
JP2009501018A (ja) 2005-07-12 2009-01-15 ザ ユニバーシティ オブ リーズ バクテリオファージ及びその使用
JP2015512255A (ja) 2012-03-17 2015-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ざ瘡の高速診断および個人化された治療
WO2016130024A1 (en) 2015-02-13 2016-08-18 Supreme Biotechnologies Limited Endolysin expression platform
JP2017505820A (ja) 2014-02-07 2017-02-23 フィクスド ファージ リミテッド 局所性および全身性細菌感染症の治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6117433A (en) * 1996-01-31 2000-09-12 Dsm N.V. Use of compositions comprising stabilized biologically effective compounds
US6034506A (en) 1998-01-16 2000-03-07 Space Systems/Loral, Inc. Lithium ion satellite battery charge control circuit
US6235033B1 (en) 2000-04-19 2001-05-22 Synthes (Usa) Bone fixation assembly
ES2569218T3 (es) * 2008-12-17 2016-05-09 Ei, Inc. Base de polvo para tratamiento del acné
BR112012003792B1 (pt) * 2009-08-21 2020-05-19 Novan Inc composição tópica, e, uso da composição tópica
KR20120115920A (ko) * 2011-04-11 2012-10-19 신라대학교 산학협력단 여드름 치료, 개선 또는 예방용 조성물
US20160338979A1 (en) * 2014-01-10 2016-11-24 The Regents Of The University Of California Skin probiotic
KR101689033B1 (ko) * 2014-06-10 2016-12-22 경북대학교 산학협력단 여드름균을 사멸시키는 여드름균 특이적 박테리오파지
US12043847B2 (en) * 2016-05-15 2024-07-23 The Regents Of The University Of California Compositions and methods for treating acne
JP7595459B2 (ja) 2017-04-21 2024-12-06 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
US20210177920A1 (en) * 2017-12-05 2021-06-17 Biomx Ltd. Bacteriophage treatment for acne and biofilms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501018A (ja) 2005-07-12 2009-01-15 ザ ユニバーシティ オブ リーズ バクテリオファージ及びその使用
JP2008297241A (ja) 2007-05-31 2008-12-11 Fujifilm Corp ニキビ用皮膚外用剤
JP2015512255A (ja) 2012-03-17 2015-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ざ瘡の高速診断および個人化された治療
JP2017505820A (ja) 2014-02-07 2017-02-23 フィクスド ファージ リミテッド 局所性および全身性細菌感染症の治療
WO2016130024A1 (en) 2015-02-13 2016-08-18 Supreme Biotechnologies Limited Endolysin expression platform

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Clinical Micriobiology Reviews，2014年，Vol.27(3)，pp.419-440
Front. Microbiol.，2017年，Vol.8:164，pp.1-11
Frontiers in Cellular and Infection Microbiology，2014年，Vol.4, Article 178，pp.1-9
Journal of Bacteriology，2007年，Vol.189(11)，pp.4161-4167
mBio，Vol. 3, Issue 5, e-00279-12，2012年，pp.1-13

Also Published As

Publication number Publication date
US20210338569A1 (en) 2021-11-04
KR20250054134A (ko) 2025-04-22
KR102799152B1 (ko) 2025-04-23
WO2018195415A1 (en) 2018-10-25
CN110799203A (zh) 2020-02-14
KR20190135054A (ko) 2019-12-05
JP7801389B2 (ja) 2026-01-16
EP3612200A4 (en) 2020-12-30
JP2024099592A (ja) 2024-07-25
AU2018255972A1 (en) 2019-10-31
CA3060415A1 (en) 2018-10-25
JP2020517735A (ja) 2020-06-18
US11903984B1 (en) 2024-02-20
US20240189220A1 (en) 2024-06-13
EP3612200A1 (en) 2020-02-26
AU2018255972B2 (en) 2024-11-21
US20240066079A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
JP7801389B2 (ja) ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
Castillo et al. Propionibacterium (Cutibacterium) acnes bacteriophage therapy in acne: current evidence and future perspectives
Liu et al. Identification of two depolymerases from phage IME205 and their antivirulent functions on K47 capsule of Klebsiella pneumoniae
Hanlon et al. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms
JP7460531B2 (ja) 微生物感染を防ぐための方法および組成物
Jończyk-Matysiak et al. Prospects of phage application in the treatment of acne caused by Propionibacterium acnes
CN103502434B (zh) 乳酸菌以及含有该乳酸菌的组合物
Machuca et al. Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum
JP6053727B2 (ja) 抗細菌組成物
Luo et al. Synergistic antibacterial effect of phage pB3074 in combination with antibiotics targeting cell wall against multidrug-resistant Acinetobacter baumannii in vitro and ex vivo
Cheleuitte-Nieves et al. Evaluation of topical lysostaphin as a novel treatment for instrumented rhesus macaques (Macaca mulatta) infected with methicillin-resistant Staphylococcus aureus
Badr et al. The therapeutic potential of cold atmospheric plasma against pathogenic bacteria inhabiting diabetic wounds
KR20250167084A (ko) 습진을 포함한 피부 질환 및 병태의 치료를 위한 조성물 및 방법
Górski Prospects of Phage Application in the Treatment of Acne Caused by
Lawrence et al. Reviving a More Than Century-Old Technology for Modern Skincare.
Sood et al. Anecdotal Evidences to Rise in Phage Therapy in Treatment of Oral Infections
WO2025183005A1 (ja) 大腸菌に対して広い抗菌スペクトルを示すバクテリオファージ
CN120796202A (zh) 一种丙酸杆菌噬菌体、裂解酶及其应用
Ong Investigating the potentials of phage therapy in burkholderia pseudomallei infection/Ong Guang Han
Han Investigating the Potentials of Phage Therapy in Burkholderia Pseudomallei Infection
Saini et al. Bacteriophages: Potential antagonistic agents against medically and agriculturally harmful bacteria
Augsburg Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241126

R150 Certificate of patent or registration of utility model

Ref document number: 7595459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150